ACI
ACAD icon

AMP Capital Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

AMP Capital Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,753
Closed -$475K – 1246
2020
Q3 		$475K Buy
11,753
+2,086
+22% +$90.1K ﹤0.01% 942
2020
Q2 		$466K Buy
9,667
+2,151
+29% +$103K ﹤0.01% 933
2020
Q1 		$311K Buy
7,516
+1,787
+31% +$73.6K ﹤0.01% 964
2019
Q4 		$247K Buy
+5,729
New +$249K ﹤0.01% 1102

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AMP Capital Investors's ACAD Position: Q4 2020 in Review

AMP Capital Investors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 11,753 shares — an estimated $475K sold.

AMP Capital Investors first reported a position in ACAD in Q4 2019 and held it in 4 quarters. The position peaked at $475K in Q3 2020. 308 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • AMP Capital Investors reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • AMP Capital Investors sold 11,753 Acadia Pharmaceuticals shares in Q4 2020, an estimated $475K.
  • AMP Capital Investors first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • AMP Capital Investors's Acadia Pharmaceuticals position peaked at $475K in Q3 2020.
  • 308 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on AMP Capital Investors's 13F filing for Q4 2020, filed 12 Feb 2021.